ACE inhibitors improve outcome after a myocardial infarction

A meta-analysis of 5966 patients with left ventricular dysfunction after a myocardial infarction enrolled in the SAVE, AIRE, and TRACE trials shows that after a median follow-up of 31 months there is a significant reduction in mortality with an angiotensin converting enzyme (ACE) inhibitor (23.4 versus 29 percent, odds ratio 0.74, p <0.0001). There is a continuing divergence in the mortality curves during follow-up that exceeds four years.